Abstract:Background: Description of immune landscapes that indulge or restrain survival and proliferation of malignant cells is critical to the improvement of therapeutic strategies. Acute myeloid leukemia (AML) remains a severe life-threatening malignancy and often confronts treatment dilemma in clinic. Although γδ T cells exhibit independent and potent cytotoxicity against leukemic cells in vitro and in the mouse models, efficacy of γδ T cell-based immunotherapy on AML patients has seemed unsatisfying so far. How the anti-AML capacity of γδ T cells is suppressed in vivo is unknown. Aims: In this study, we aim to dissect the abnormal changes and functions of intrinsic γδ T cells in the context of AML and dig out the correlated factors in the AML tumor environment. Methods: 1. Immunophenotyping analyses of γδ T cells in bone marrows from newly diagnosed AML patients (n = 62) were detected using flow cytometry, compared with healthy donors (n=51). The levels of TGF-β family members in the supernatants of bone marrows were detected by ELISA kits. 2. Peripheral blood mononuclear cells (PBMCs) isolated from healthy donors were stimulated with AML blasts and morphogenetic protein 2 (BMP2) to validate clinical phenotypes. Functional experiments were performed to depict the role of a BMP2-induced subset of γδ T cells in the anti-AML activity of effector γδ T cells. 3. To confirm the findings described above, we established human CD34+ cells-implanted mice models followed by injection with luciferase and GFP co-expressing AML cells. Results: The proportions of total γδ T cells and Vδ1+ fraction were not significantly different between AML patients and donors. In contrast, the percentage of Vδ2+ T cells was markedly decreased in AML patients. Meanwhile, a key activating receptor of γδ T cells, NKG2D, was dramatically decreased and regulatory receptors CD25 and PD-1 were increased on Vδ2+ T cells in AML patients. The expansion capacity of Vδ2+ T cells was profoundly impaired in AML patients. The functional impairments of γδ T cells were accompanied with an abnormally increased levels of BMP2, rather than TGF-β, BMP4 and ActivinA, in AML patients. Furthermore, we demonstrated that BMP2 directly induced an aberrant γδ T cells subset expressing Vδ2+CD25+CD127low (abbreviated as BMP2-Vδ2) in PBMCs from healthy donors. Consistently, BMP2-Vδ2 cells were significantly increased in the bone marrows of AML patients compared with donors. The frequencies of BMP2-Vδ2 cells correlated to soluble BMP2 levels and the disease status. Distinct from effector Vδ2 cells, BMP2-Vδ2 not only lost the ability of killing AML cells, but also was able to reduce the anti-AML activity of effector Vδ2 cells after co-cultures. In AML-loaded humanized mice, treatment with BMP2 induced the occurrence of BMP2-Vδ2 cells and reduced the survival rate of mice. Injection of BMP2-Vδ2 cells significantly attenuated the activity of effector Vδ2 cells on the elimination of AML cells in mice. Together, these results demonstrated the immunoregulatory effect of BMP2 on the phenotype and function of γδ T cells in AML microenvironment. Summary/Conclusion: We first reported that dysregulated BMP2 in AML triggered an immunosuppressive subset of γδ T cells, leading to the impairment of anti-AML function of effector γδ T cells. Our findings provide a novel insight into the mechanisms of immunosuppression in the context of leukemia and suggest potential targets for the treatment of AML and other hematopoietic malignancies.

Gm40600 promotes CD4+ T-cell responses by interacting with Ahnak

Modulating the Conformation of the TIR Domain by a Neoteric MyD88 Inhibitor Leads to the Separation of GVHD from GVT.

Qa-1(b)-dependent modulation of dendritic cell and NK cell cross-talk in vivo.

Mechanisms of Cpg-Induced Cd40 Expression on Murine Bone Marrow-Derived Dendritic Cells

Regulation of cytokine expression by an autoreactive B cell clone derived from MRL/MP-lpr/lpr mice

Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help.

Mechanism of Enhancement of the CTL Activity in Mice Co-Expressing CD80, CD86 and CD137Lgenes

Calcium/Calmodulin-Dependent Protein Kinase IV Mediates IFN-γ-Induced Immune Behaviors in Skeletal Muscle Cells

S124: BONE MORPHOGENETIC PROTEIN 2 TRIGGERS OFF AN IMMUNOSUPPRESSIVE EFFECT OF ΓΔ T CELLS IN ACUTE MYELOID LEUKEMIA

Protective Effect of Human CD40-Ig Fusion Protein in a Murine Model of Acute Graft-Versus-host Disease.

The Transcription Factor Zfp335 Promotes Differentiation and Survival of Effector Th1 Cells by Directly Regulating Lmna Expression

The helminth TGF-β mimic TGM4 is a modular ligand that binds CD44, CD49d and TGF-β receptors to preferentially target myeloid cells

Study of the inducing effects of GM-CSF plasmid on pre-DC from murine bone marrow in vivo

Chinese herbal formula, modified Guilu Erxian glue, alleviates apoptosis of hematopoietic stem cells by regulating SLAM-SAP signal pathway in aplastic anemia mice model

Preparation and Characterization of Monoclonal Antibodies Against GAM Protein: A Novel Gp130-Associated Molecule

CD44 Acts As a Coreceptor for Cell-Specific Enhancement of Signaling and Regulatory T Cell Induction by TGM1, a Parasite TGF-β Mimic

B7H1-Ig fusion protein activates the CD4(+) IFN-gamma receptor(+) type 1 T regulatory subset through IFN-gamma-secreting Th1 cells

hsBAFF enhances activity of NK cells by regulation of CD4+ T lymphocyte function

A Tetrameric Form of CD40 Ligand with Potent Biological Activities in Both Mouse and Human Primary B Cells.

Dhx33 promotes B-cell growth and proliferation by controlling activation-induced rRNA upregulation

Alkylglycerols modulate the proliferation and differentiation of non-specific agonist and specific antigen-stimulated splenic lymphocytes.